Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri) European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS). more ➔
Agomab extenses Series B with USD40m Bringing Total Amount to USD114m Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount … more ➔
Spatial Biology Company Navinci (Olink) closes EUR9m Series A Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round … more ➔
ADC, cancer, Chris Martin, Lausanne, orphan, Sobi, Swedish, Zynlonta Swedish SOBI awarded rights to market Zynlonta from ADC therapeuticsIn a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US. more ➔
bioeconomy, biosyntia, bonn, brandkamp, circular, denmark, ECBF, financing, fund ECBF joins Novo Seeds and Sofinnova Partners in EUR11.5m round in BiosyntiaThe European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused … more ➔
Lonza invests CHF500m in Large-Scale Facility in Stein (CH) Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m. more ➔
Evotec, Boehringer Ingelheim, and bioMérieux launch AurobacEvotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR). more ➔
Urovant Sciences cashes in $75m in licence deal from Pierre FabreFrench drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe. more ➔
CureVac NV sues BioNTech for IP infringementGerman mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents. more ➔
French Ipsen falls after Epizyme take-over announcementShares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m. more ➔
